Oluwafemi Ajimotokan
Research Subjects
Oluwafemi Ajimotokan has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Aderemi Oluyemi
ReMay Consultancy and Medical Services, Ikeja, Nigeria
1 shared publication- Ajayi Oluwatomisin Temidayo
Faculty of Pharmacy, University of Lagos, Lagos, Nigeria
1 shared publication - Awoyinfa Michael Mbbs Oluwatobiloba
College of Medicine, University of Lagos, Lagos, Nigeria
1 shared publication - Chimezirim Ezeano
University of Nigeria Teaching Hospital, Ituku, Nigeria
1 shared publication - Emmanuel Elorm Nortey-Adom
Department of Medicine, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA
1 shared publication - Emmanuel Kokori
University of Ilorin, Ilorin, Nigeria
1 shared publication
Latest Publications
- Open Access
- 25 November 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 548-553
Is there hope for HER2-positive colorectal cancer with Trastuzumab? A review of current evidence
Trastuzumab combinations are emerging as a promising therapeutic strategy for HER2-positive colorectal cancer. This review investigates the current clinical data on efficacy and safety. Clinical trials have shown encouraging results, with objective response rates (ORRs) ranging from 22.2 to 46% and complete remission achievable in some patients. Additionally, these combinations demonstrate potential for improved overall survival (OS). However, optimizing therapeutic strategies remains crucial. Future research should tailor treatment regimens based on tumor biology and individual patient characteristics. Investigating ctDNA genotyping as a reliable method for identifying responders and exploring the role of Rat Sarcoma Virus (RAS) mutations and other molecular markers are key areas for optimizing patient selection and treatment efficacy. Understanding resistance mechanisms is vital for developing combination therapies that overcome these pathways.
- 25 November 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (1) , 548-553
Open AccessIs there hope for HER2-positive colorectal cancer with Trastuzumab? A review of current evidence
Trastuzumab combinations are emerging as a promising therapeutic strategy for HER2-positive colorectal cancer. This review investigates the current clinical data on efficacy and safety. Clinical trials have shown encouraging results, with objective response rates (ORRs) ranging from 22.2 to 46% and complete remission achievable in some patients. Additionally, these combinations demonstrate potential for improved overall survival (OS). However, optimizing therapeutic strategies remains crucial. Future research should tailor treatment regimens based on tumor biology and individual patient characteristics. Investigating ctDNA genotyping as a reliable method for identifying responders and exploring the role of Rat Sarcoma Virus (RAS) mutations and other molecular markers are key areas for optimizing patient selection and treatment efficacy. Understanding resistance mechanisms is vital for developing combination therapies that overcome these pathways.
- Open Access
- 1 July 2024
- Published by Medknow in NIGERIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Vol. 16 (2) , 57-61
Radiation proctitis in Lagos, Nigeria: A Review of clinical, endoscopic, and pathological findings
Background and Objectives: Radiation proctitis (RP) is only sparsely documented as a gastrointestinal side effect of the administration of radiotherapeutic interventions in oncology practice in Nigerian patients. This review sought to profile important clinical aspects in five such cases of RP along with a review of the endoscopic and pathological findings. Materials and Methods: We conducted a retrospective review of all patients who were diagnosed with RP at two Lagos-based privately run colonoscopy centers. The record examined covered a duration of 36 months (April 1, 2016–May 31, 2019). Over this period, 1035 colonoscopies were carried out, and all RP cases (n = 5) were identified. The clinical presentations and endoscopic findings were documented as well as the findings of the pathologists’ report for the chronic proctitis (CP) cases. Results: All patients were in their sixth or seventh decade of life (age range, 63–78 years). There were two males and three females. All subjects had haematochezia as their presenting complaint. In the case of the two patients with acute RP, bleeding commenced after initiation of radiotherapy. As for the three patients with CP, the above symptoms started at 7, 11, and 36 months, respectively, after the last dose of radiotherapy. The time from the onset of the symptom to seeking colonoscopy evaluation varied between 2 and 12 weeks. The histological findings of biopsies of CP were consistent with the diagnosis in the three cases. The endoscopic findings were classified using the Radiation Therapy Oncology Group and the European Organization for Research and Treatment of Cancer criteria. Conclusion: This study documents the changes related to RP in a cohort of Nigerian patients, with a focus on clinical, endoscopic, and histopathological findings.
- 1 July 2024
- Published by Medknow in NIGERIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Vol. 16 (2) , 57-61
Open AccessRadiation proctitis in Lagos, Nigeria: A Review of clinical, endoscopic, and pathological findings
Background and Objectives: Radiation proctitis (RP) is only sparsely documented as a gastrointestinal side effect of the administration of radiotherapeutic interventions in oncology practice in Nigerian patients. This review sought to profile important clinical aspects in five such cases of RP along with a review of the endoscopic and pathological findings. Materials and Methods: We conducted a retrospective review of all patients who were diagnosed with RP at two Lagos-based privately run colonoscopy centers. The record examined covered a duration of 36 months (April 1, 2016–May 31, 2019). Over this period, 1035 colonoscopies were carried out, and all RP cases (n = 5) were identified. The clinical presentations and endoscopic findings were documented as well as the findings of the pathologists’ report for the chronic proctitis (CP) cases. Results: All patients were in their sixth or seventh decade of life (age range, 63–78 years). There were two males and three females. All subjects had haematochezia as their presenting complaint. In the case of the two patients with acute RP, bleeding commenced after initiation of radiotherapy. As for the three patients with CP, the above symptoms started at 7, 11, and 36 months, respectively, after the last dose of radiotherapy. The time from the onset of the symptom to seeking colonoscopy evaluation varied between 2 and 12 weeks. The histological findings of biopsies of CP were consistent with the diagnosis in the three cases. The endoscopic findings were classified using the Radiation Therapy Oncology Group and the European Organization for Research and Treatment of Cancer criteria. Conclusion: This study documents the changes related to RP in a cohort of Nigerian patients, with a focus on clinical, endoscopic, and histopathological findings.